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macrophages increased the adhesion of tumour cells to 
lymphatic and blood endothelium. Secretion of IL-1β was 
caspase-1 dependent, and treatment with caspase-1 inhibi-
tor reduced IL-1β production by 73% and concomitantly 
reduced tumour cell adhesion to levels obtained with resting 
macrophages. Transmigration of MDA-MB-231 cells across 
blood and lymphatic endothelial monolayers was signifi-
cantly increased following IL-1β stimulation. Furthermore, 
supernatants from activated macrophages increased transmi-
gration of MDA-MB-231 cells across endothelial monolay-
ers, which was abolished by caspase-1 inhibition. IL-1β stim-
ulation of tumour cells significantly increased their migratory 
ability and a significant increase in migration was observed 
when MDA-MB-231 cells were stimulated with macrophage 
conditioned media (two of three donors). Results demonstrate 
that macrophage production of IL-1β plays an important role 
in the migration of breast cancer cells and their adhesion to, 
and transmigration across, blood and lymphatic endothelial 
cells. Results suggest that IL-1β may play a role in the adhe-
sion to lymphatic endothelial cells in particular.
Keywords Interleukin-1 · Breast cancer · Macrophage · 
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Abbreviations
bFGF  Basic fibroblast growth factor
CLEVER-1  Common lymphatic endothelial and 
vascular endothelial receptor
EBM  Endothelial basal media
EGF  Epidermal growth factor
HIF-1α  Hypoxia-inducible factor
hMEC-1  Human microvascular endothelial 
cells
HMVEC-dLy Neo  Neonatal dermal lymphatic microvas-
cular endothelial cells
Abstract Lymphovascular invasion (LVI), encompassing 
blood and lymphatic vessel invasion, is an important event 
in tumourigenesis. Macrophages within the tumour microen-
vironment are linked to the presence of LVI and angiogen-
esis. This study investigates the role of macrophage-derived, 
caspase-1-dependent interleukin-1beta (IL-1β) in an in vitro 
model of LVI. IL-1β significantly augmented the adhe-
sion and transmigration of breast cancer cell lines MCF7 
and MDA-MB-231 across endothelial cell barriers. MDA-
MB-231 and MCF7 showed a higher percentage of adhe-
sion to lymphatic endothelial cells than blood endothelial 
cells following endothelial cell IL-1β stimulation (P < 0.001 
and P < 0.0001, respectively). Supernatants from activated 
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hTERT-LEC  Human telomerase reverse tran-
scriptase immortalised lymphatic 
endothelial cells
HUVEC  Human umbilical cord vein endothe-
lial cells
ICAM-1  Intracellular adhesion molecule
ICE  IL-1β-converting enzyme
IL  Interleukin
IL-1β  Interleukin-1beta
LPS  Lipopolysaccharide
LVI  Lymphovascular invasion
M-CSF  Macrophage colony stimulating factor
PBMC  Peripheral blood mononuclear cells
STR  Short tandem repeat
TDL  Tumour-derived lysate
TNF  Tumour necrosis factor
VCAM-1  Vascular cell adhesion molecule
VEGF  Vascular endothelial growth factor
Introduction
Lymphovascular invasion (LVI), encompassing both blood 
and lymphatic vessel invasion, is an important event in 
tumourigenesis and is an initial prerequisite step in metas-
tasis. LVI is strongly associated with adverse patient prog-
nosis in a number of tumour types, with studies showing 
that in certain tumour types, including breast cancer and 
melanoma, LVI occurs more frequently in lymphatic ves-
sels as opposed to blood vessels [1–4]. The presence of 
macrophages within the tumour microenvironment has 
been linked to the presence of LVI and angiogenesis [1, 
5, 6]. Macrophages are recruited by chemotactic factors 
expressed by tumours and the factors they express can 
affect tumour cell behaviour; some of the most widely 
described factors produced by macrophage that can 
alter angiogenesis are vascular endothelial growth fac-
tor (VEGF), and angiopoietin 1 (reviewed in [7]). Certain 
studies have reported that perivascular macrophages are 
involved in tumour cell intravasation without concomitant 
induction of angiogenesis [8].
Despite the link between immune cells within the 
tumour environment and the presence of LVI only a small 
number of factors have been identified that may have the 
ability promote vascular invasion, with most studies focus-
sing upon factors that potentially influence blood vessel 
invasion. Cytokines are a loose category of small glycopro-
teins, including interleukins, interferons, chemokines and 
tumour necrosis factor (TNF). They are produced by a wide 
range of cells, notably immune cells and also endothelial 
cells, fibroblasts, and various tumour and stromal cells. A 
number of cytokines, such as interleukin (IL)-8 and TNF-
α, are expressed at high levels by macrophages and can 
reportedly alter both angiogenesis and metastatic dissemi-
nation of tumour cells [9, 10].
The interleukin (IL)-1 superfamily consists of IL-1α, 
IL-1β and others such as IL-18 and IL-13; and IL1-RA 
(receptor agonist) which functions to modulate IL-1α 
and IL-1β activity (reviewed in [11]). IL-1β is a multi-
functional pro-inflammatory cytokine principally pro-
duced by hematopoietic cells such as macrophages and 
monocytes, and also by epithelial cells, and expression 
is associated with angiogenesis and the invasive abili-
ties of tumour cells [12, 13]. IL-1β is linked to increased 
metastasis in various in vivo models [14] and has been 
linked with bone-homing in breast cancer. IL-1β expres-
sion has been shown to be expressed in the breast tumour 
microenvironment, at higher levels in invasive breast 
lesions than benign conditions and ductal in situ carci-
noma [13, 15]. Caspase-1, or IL-1β-converting enzyme 
(ICE), is a cysteine protease responsible for activation of 
the IL-1β and IL-18 precursors to the pro-inflammatory 
active cytokines. Studies have suggested that caspase-1 
expression is decreased in prostate cancer [16] and colon 
cancer [17].
This study aimed to investigate whether IL-1β can differ-
entially modulate in vitro tumour cell adhesion and trans-
migration to, and across, blood and lymphatic endothelium 
and to assess its ability to alter tumour cell migration. We 
also sought to determine the effect on these phenotypic 
endpoints following stimulation with macrophage condi-
tioned media alone and in combination with a caspase-1 
inhibitor.
Materials and methods
Cell lines and culture
Breast cancer cell lines MCF7 and MDA-MD-231, 
large vein endothelial cells from human umbilical cords 
(HUVEC), human microvascular endothelial cells hMEC-
1, human telomerase reverse transcriptase immortalised 
lymphatic endothelial cells (hTERT-LEC) and neona-
tal dermal lymphatic microvascular endothelial cells 
(HMVEC-dLy Neo) were used in this study.
Breast cancer cell lines were obtained from the ATCC 
and used within a 15 passage window. MCF-7 were main-
tained in RPMI-1640 (Sigma), 10% iron-supplemented 
donor calf serum (PAA laboratories) with 1% penicil-
lin/streptomycin (Sigma). MDA-MB-231 were main-
tained in minimal essential medium EAGLE (Sigma), 
0.1 mM non-essential amino acids solution (Sigma), 
2 mM l-glutamine (Sigma), 1% penicillin/streptomycin 
and 1% iron-supplemented donor calf serum. HUVEC 
were isolated as previously described [18, 19] and used 
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between passage 2 and 6. HUVEC were maintained in 
37% nutrient mixture F-12 HAM media (Sigma) in ster-
ile water containing 3.7% 199 media (Sigma), 20% iron-
supplemented donor calf serum, 1% sodium bicarbonate 
(Sigma), 14 mM HEPES (Sigma), 2 mM l-glutamine, 
1% penicillin/streptomycin, 7.5U/ml heparin (CP Phar-
maceuticals), 25 ng/ml epidermal growth factor (EGF) 
(Peprotech) and 12.5 ng/ml basic fibroblast growth factor 
(bFGF) (Peprotech). Human microvascular endothelial 
cells hMEC-1 [20], obtained from ATCC, were grown in 
endothelial basal medium (Lonza, USA) with 10% iron-
supplemented donor calf serum, 1 μg/ml hydrocortisone 
(Sigma), 10 ng/ml EGF and 1% penicillin/streptomycin 
and used between passage 4 and 18. hTERT-LEC were 
a kind gift from Nissato and Pepper [19, 21, 22] and 
were maintained in endothelial basal media (EBM) sup-
plemented with the EGM-2 bullet kit (Lonza) and used 
between passage 27 and 34. HMVEC-dLy Neo (Lonza), 
a primary lymphatic cell line, was cultured in the same 
medium as hTERT-LEC and used between passage 4 and 
6. Cell lines were routinely tested for mycoplasma and 
tumour cells have been subsequently verified using mul-
tiplex short tandem repeat (STR) system (Powerplex 16, 
Promega).
Tumour-conditioned media were generated from con-
fluent tumour cell monolayers which were then cultured 
in HUVEC or hTERT-LEC basal medium without serum 
or growth factors for 24 h. Prior to experimental use, 
tumour-conditioned media were supplemented with iron-
supplemented donor calf serum and 50 U/ml polymyxinB-
sulphate (Sigma). Tumour-derived lysate (TDL), used for 
macrophage stimulation, was generated from 1 × 107 cells 
subjected to five cycles of freeze–thaw using liquid nitro-
gen and a 37 °C water bath. Debris was removed by cen-
trifugation and cleared lysates stored at −80 °C.
Healthy donor peripheral blood, obtained with the 
approval of the relevant ethical review board (BT20052010, 
University of Nottingham Medical School Ethics Commit-
tee), was fractionated using Histopaque 1077 (Sigma) to 
obtain peripheral blood mononuclear cells (PBMC) [19, 
23]. Monocytes were isolated from PBMC using para-
magnetic particles conjugated with anti-CD14 antibodies 
(Miltenyi Biotec) and were >95% pure as determined by 
flow cytometry. Macrophages were generated by culturing 
CD14 + monocytes for 6 days in RPMI-1640 medium with 
10% foetal calf serum in the presence of 50 ng/ml of mac-
rophage colony stimulating factor (M-CSF) (Peprotech) 
in Teflon flasks (Thermo Scientific). Macrophage pheno-
type was confirmed by flow cytometry (CD68+, CD14+, 
MHC II+) and conditioned media harvested on day 7. 
IL-1β production by macrophages was induced by stimu-
lating cells with tumour-derived lysate, lipopolysaccharide 
(LPS) (Invivogen) and a combination of tumour-derived 
lysate and LPS with and without caspase-1 inhibitor (R&D 
Systems).
Static adhesion and migration assays
The assays have been described previously [19]. Briefly, 
static adhesion assays used a confluent endothelial mon-
olayer that remained unstimulated, or was stimulated with 
IL-1β for 24 h. Tumour cell adhesion was assessed after 
35 min, following cell labelling with 1 μM of Cell Tracker 
Green CMFDA (Invitrogen). Adherent tumour cells were 
counted using a fluorescence microscope (Nikon). Two fields 
of view were counted in each well at 20× magnification. 
Results were expressed as the percentage of cells adhered 
relative to control. PBMC adhesion controls were run imme-
diately prior to each experiment to demonstrate that the 
endothelial cells and cytokine were responding appropri-
ately. In migration assays, a confluent tumour cell monolayer 
remained unstimulated or was stimulated with IL-1β (5 ng/
ml) for 24 h. Mitomycin C (Sigma) was included (10 µg/ml) 
to inhibit cellular proliferation. Migration was monitored at 
different time points following a scratch to create an area 
devoid of adherent cells. Percentage reduction of the scratch 
area at different time points was measured using ImageJ 
1.43u software (National Institute of Health).
Transmigration assay
A confluent endothelial cell monolayer was grown on Boyden 
Chamber Transwell inserts and remained unstimulated or was 
stimulated with IL-1β (10 ng/ml) for 24 h. The confluency 
and integrity of the endothelial barrier was demonstrated by 
preventing lucifer yellow leakage (Sigma). Tumour cell trans-
migration was assessed following cell labelling with 5 nM 
of Cell Tracker Green CMFDA (Invitrogen). Transmigra-
tion was monitored, by counting cells on the underside of the 
chamber, after 16 h using a fluorescence microscope (Nikon). 
Experiments were conducted twice, both in duplicate.
Elisa
Expression of IL-1β in tumour conditioned media and mac-
rophage conditioned media was conducted using a human 
IL-1β/IL-1F2 duoset ELISA development kit (R&D Systems) 
according to the manufacturers’ protocols. Briefly, a 96-well 
plate was coated with capture antibody overnight and the 
plate was washed and blocked with bovine serum albumin. 
Samples and IL-1β recombinant protein standard were added 
to the plate for 2 h. This was followed by detection antibody 
for 2 h and streptavidin-HRP for 20 min, with each step pre-
ceded by a wash. Colour change was achieved by the addition 
of substrate followed by a stop solution, and the plate was 
read at 450 nm on a BMG Fluostar Optima (BMG Labtech).
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Statistics
Data analysis was performed in Microsoft Excel 2007 and 
Graph Pad Prism. Statistical significance was determined 
using the independent samples t test (two tailed), P > 0.05 
was deemed significant in this study.
Results
Tumour cell adhesion to endothelial cells is increased 
by IL‑1β
Conditioning blood or lymphatic endothelial cells with 
IL-1β for 24 h significantly increased the adhesion of 
both MDA-MB-231 and MCF7 cells (Fig. 1a, b). Both 
MDA-MB-231 and MCF7 showed a higher percentage 
of adhesion to lymphatic endothelial cells than blood 
endothelial cells following endothelial cell IL-1β stimu-
lation (P < 0.001 and P < 0.0001, respectively). Adhe-
sion levels of tumour cell lines to endothelial cell models 
under control conditions have been previously published 
[19]. As with endothelial cell stimulation, 24-h IL-1β 
stimulation of tumour cells alone caused significant 
increase of both MDA-MB-231 and MCF7 adhesion 
(Fig. 1) to blood and lymphatic endothelial cells with 
MDA-MB-231 tumour cells having a significantly higher 
level of adhesion to lymphatic endothelial cells. When 
both tumour cells and endothelial cells were simultane-
ously conditioned with IL-1β, adhesion was more mark-
edly increased than when following stimulation of either 
cell type alone (Fig. 1e).
Fig. 1  Tumour cell adhesion to 
blood and lymphatic endothe-
lium with and without IL-1β 
stimulation. a MDA-MB-231 
and b MCF7 adhesion to IL-1β-
stimulated HUVEC (grey), 
hMEC-1 (grey striped), hTERT-
LEC (black) and HMVEC-dLy 
Neo (black striped) endothelial 
cells. c IL-1β stimulated MDA-
MB-231 and d IL-1β stimulated 
MCF7 adhesion to unstimulated 
endothelial cells. e IL-1β stimu-
lated MDA-MB-231 adhesion 
to IL-1β-stimulated hMEC-1 
(grey striped) or hTERT-LEC 
(black) cells. Statistical signifi-
cance (P < 0.05) determined by 
t test compared to control group 
is indicated by an asterisk, error 
bars represent standard devia-
tion. Statistical significance 
between blood and lymphatic 
endothelium is represented by 
double dagger
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Activated macrophages promote tumour cell adhesion 
to endothelial cells
When macrophages from different donors were activated 
with LPS they secreted IL-1β at varying levels (18–270 pg/
ml). Supernatants from LPS activated, but not resting, 
macrophages markedly increased the adhesion of MDA-
MB-231 or MCF7 cells to lymphatic and blood endothe-
lium (Fig. 2a–c). In contrast, tumour conditioned media 
had no impact on the adhesion of tumour cells to either 
endothelium (data not shown). Treatment of macrophages 
with caspase-1 inhibitor reduced secreted IL-1β produc-
tion by a mean of 73% and concomitantly reduced tumour 
cell adhesion to levels obtained with resting macrophages 
(Fig. 2a–c). Activation of macrophages in the presence of 
tumour-derived lysate also ablated their capacity to pro-
mote adhesion to endothelial monolayers.
IL‑1β supports the migratory ability of tumour cells
Stimulation of MDA-MB-231 and MCF7 tumour cells with 
IL-1β caused a significant increase in migration, observed 
from 2 h in MDA-MB-231 cells and from 24 h in MCF7 
cells (Fig. 3a, b). In contrast, tumour-conditioned media 
did not alter migration of MDA-MB-231 or MCF7 cells 
(data not shown). Two of the three macrophage-conditioned 
media significantly increased migration of MDA-MB-231 
(Fig. 3c). It was noted that macrophage-derived IL-1β lev-
els in the responding donors were 270 and 137 pg/ml whilst 
for the non-responding donor there was a much lower level 
(20 pg/ml). Further analysis showed that the level of IL-1β 
secreted by activated macrophages corresponded with the 
rate of tumour cell migration.
We previously established that the primary route of 
breast tumour metastasis is through lymphatic vessels [2]. 
We therefore determined the relative capacity of breast 
tumour cells to traverse blood or lymphatic vessels. A tissue 
culture model was established using monolayers of blood 
(hMEC-1) or lymphatic endothelial cells (hTERT-LEC) and 
the migration of cell lines studied. The addition of IL-1-β 
to the endothelial monolayer significantly increased tumour 
cell migration (Fig. 4a). However, there was no preference 
for migration through lymphatic monolayers. Addition 
of the conditioned medium from activated macrophages 
increased the transmigration of MDA-MB-231 cells 
through both blood and lymphatic endothelial cell barriers 
(Fig. 4b–d). Importantly, the increased level of transmigra-
tion was abrogated by inclusion of a caspase-1 inhibitor.
Fig. 2  MDA-MB-231 adhesion to macrophage conditioned media 
stimulated hMEC-1 (grey striped) and hTERT-LEC (black) from 
three different donors (a–c). Tables indicate macrophage treatment 
prior to harvesting macrophage conditioned media. LPS LPS stimula-
tion, TDL tumour-derived lysate stimulation, C1i caspase-1 inhibitor. 
Statistical significance (P < 0.05) determined by t test compared to 
control group is indicated by an asterisk, error bars represent stand-
ard deviation. Statistical significance between blood and lymphatic 
endothelium is represented by double dagger
▸
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Discussion
The aims of this study were to determine the role of IL-1β 
on adhesion and transmigration to and across endothe-
lial cell monolayers, and whether macrophage might be 
involved in this process. Studies have shown that lymphatic 
vessel invasion is more prevalent in patient tumours and is 
associated with prognosis in numerous tumour types [1, 2].
Following stimulation of endothelial cells with recom-
binant IL-1β, tumour cell adhesion to blood and lym-
phatic endothelial cell monolayers increased; however, a 
larger increase was observed in cells of lymphatic origin. 
Similar results were observed when MDA-MB-231 cells 
were stimulated with IL-1β and added to unstimulated 
endothelial cell monolayers. Interestingly, the prefer-
ence for MCF7 cells to adhere to lymphatic over blood 
endothelial cell monolayers when the endothelial cells 
were stimulated with IL-1β was not replicated when 
the MCF7 cells were stimulated with IL-1β and added 
to unstimulated endothelial cells. A substantial increase 
in MDA-MB-231 adhesion was observed following 
endothelial cell stimulation with macrophage-conditioned 
media from stimulated macrophages. Interestingly, dual 
incubation with LPS and a caspase-1 inhibitor ablated the 
increase in tumour cell adhesion to endothelial cell mon-
olayers and was associated with a large reduction (62–
83%) in the amount of IL-1β present in the macrophage-
conditioned media. Tumour-conditioned media had no 
effect on adhesion and did not contain secreted IL-1β, 
which is in agreement with previous studies [24].
LPS-stimulated macrophage conditioned media 
increased transmigration of MDA-MB-231 across both 
blood and lymphatic endothelium, which could be ablated 
by including a caspase-1 inhibitor; clearly implicating 
IL-1β as an important mediator in adhesion and transmi-
gration. Interestingly, in two of three macrophage donors, 
preferential transmigration across lymphatic endothelium 
was observed. A study has shown the effect of macrophage 
conditioned media on MCF7 adhesion to HUVEC which 
could be reduced with endothelin receptor inhibition and 
showed similar results for transmigration [25].
We postulate that IL-1β may cause differential expres-
sion of adhesion molecules on lymphatic over blood 
endothelium; we observed an increase of both intracellu-
lar adhesion molecule (ICAM)-1 and vascular cell adhe-
sion molecule (VCAM)-1 cell surface expression but to 
equal levels across HUVEC, hMEC-1 and HTERT-LEC 
following IL-1β stimulation, with no change in common 
lymphatic endothelial and vascular endothelial recep-
tor (CLEVER)-1 expression (data not shown). IL-1β has, 
Fig. 3  a MDA-MB-231 migration in control conditions (black line) 
or following stimulation with IL-1β (grey line). b MCF7 migration 
in control conditions (black line) or following stimulation with IL-1β 
(grey line). c MDA-MB-231 migration in control conditions (black 
line) or following stimulation with macrophage-conditioned media 
from three individual different donors (grey lines). Statistical signifi-
cance (P < 0.05) determined by t test compared to control group is 
indicated by an asterisk, error bars represent standard deviation
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however, been shown to promote metastasis in a number of 
tumour types, such as lung cancer [26] and melanoma [14].
In addition to adhesion and transmigration, stimula-
tion of both MDA-MB-231 and MCF7 tumour cells with 
IL-1β increased their migratory ability; furthermore, this 
increase was also observed with macrophage conditioned 
media and could be inhibited with a caspase-1 inhibitor. 
Previous studies have shown that IL-1β can modulate the 
migratory potential of MDA-MB-231 cells through accu-
mulation of hypoxia-inducible factor (HIF)-1α, a principal 
regulator of genes induced by hypoxia [27, 28]. In vivo 
studies have identified that increased expression of IL-1β 
is associated with a bone-seeking clone of MDA-MB-231 
cells indicating a role for IL-1β in facilitating bone-hom-
ing in the process of bone metastasis [29, 30].
The in vitro studies described modelled single pheno-
typic events and were able to clearly show that IL-1β or 
macrophage-derived IL-1β enhanced adhesion, migration 
and transmigration. These data suggest that IL-1β is impor-
tant for adhesion and transmigration of tumour cells and is 
likely to be involved in lymphatic vessel invasion.
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